{"id":"solu-medrol-or-placebo-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes (euphoria, anxiety)"},{"rate":null,"effect":"Infection risk (immunosuppression)"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylprednisolone is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This results in decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced migration and activation of immune cells. The intravenous formulation (Solu-Medrol) provides rapid systemic anti-inflammatory and immunosuppressive effects.","oneSentence":"Solu-Medrol (methylprednisolone sodium succinate) is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting pro-inflammatory cytokine production and immune cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:47.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute inflammatory and autoimmune conditions (e.g., multiple sclerosis exacerbations, rheumatoid arthritis flares)"},{"name":"Severe allergic reactions"},{"name":"Organ transplant rejection prophylaxis"},{"name":"Cerebral edema"},{"name":"Spinal cord injury (acute phase)"}]},"trialDetails":[{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy","enrollment":163},{"nctId":"NCT03584516","phase":"PHASE2, PHASE3","title":"GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-01-17","conditions":"Chronic Graft-versus-host Disease","enrollment":155},{"nctId":"NCT03139604","phase":"PHASE3","title":"GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-07-19","conditions":"Graft-versus-host Disease (GVHD)","enrollment":439},{"nctId":"NCT04323566","phase":"PHASE2","title":"Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement","status":"ENROLLING_BY_INVITATION","sponsor":"Uppsala University Hospital","startDate":"2022-05-01","conditions":"Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia","enrollment":40},{"nctId":"NCT02798068","phase":"PHASE4","title":"Steroids and Microcirculation In Cardiac Surgery","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2016-05","conditions":"C.Surgical Procedure, Cardiac","enrollment":40},{"nctId":"NCT01308255","phase":"PHASE4","title":"Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2006-09","conditions":"Rheumatoid Arthritis","enrollment":112},{"nctId":"NCT00104299","phase":"PHASE2, PHASE3","title":"Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":197},{"nctId":"NCT02571517","phase":"PHASE4","title":"Glucocorticoid Therapy Impact on the Inflammatory Response and Clinical Evolution in Patients With Severe Bronchiolitis","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2011-11","conditions":"Bronchiolitis, Viral","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35167,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Solu-medrol 500mg IV BE145214","Solu-medrol 500mg IV H02AB04","Solu-medrol 500mg IV SUB14562MIG","Solu-medrol 500mg IV 277S102F12"],"phase":"marketed","status":"active","brandName":"Solu-medrol or placebo administration","genericName":"Solu-medrol or placebo administration","companyName":"Erasme University Hospital","companyId":"erasme-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Solu-Medrol (methylprednisolone sodium succinate) is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting pro-inflammatory cytokine production and immune cell activation. Used for Acute inflammatory and autoimmune conditions (e.g., multiple sclerosis exacerbations, rheumatoid arthritis flares), Severe allergic reactions, Organ transplant rejection prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}